Ionizing radiation causes DNA damage and is a mainstay for cancer treatment, but
understanding of its genomic impact is limited. We analyzed mutational spectra following …

Radiotherapy is not currently informed by the genetic composition of an individual patient's
tumour. To identify genetic features regulating survival after DNA damage, here we conduct …

Ionizing radiation is a potent carcinogen, inducing cancer through DNA damage. The
signatures of mutations arising in human tissues following in vivo exposure to ionizing …

Radiotherapy is involved in many curative treatments of cancer; millions of survivors live with
the consequences of treatment, and toxicity in a minority limits the radiation doses that can …

Adverse reactions in normal tissue after radiotherapy (RT) limit the dose that can be given to
tumour cells. Since 80% of individual variation in clinical response is estimated to be caused …

Radiogenomics is the whole genome application of radiogenetics, which focuses on
uncovering the underlying genetic causes of individual variation in sensitivity to radiation …

The occurrence of acute or late normal tissue reactions after therapeutic radiotherapy and
cellular responses in in vitro radiosensitivity assays do not correlate well suggesting that to …

The advent of affordable and rapid next-generation DNA sequencing technology, along with
the US Supreme Court ruling invalidating gene patents, has led to a deluge of germline and …

Radiation therapy is a key modality in the treatment of cancer. Substantial progress has
been made in unraveling the molecular events which underpin the responses of malignant …

A key challenge in radiotherapy is to maximize radiation doses to cancer cells while
minimizing damage to surrounding healthy tissue. As severe toxicity in a minority of patients …